Vigabatrin dosing during haemodialysis

Seizure

Volumn 5, Issue 3, 1996, Pages 239-242

  Bachmann, Daniella ^a   Ritz, Rudolf ^a   Wad, Nils ^b   Haefeli, Walter E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SWISS EPILEPSY CENTER   (Switzerland)

Author keywords

Haemodialysis; Pharmacokinetics; Vigabatrin

Indexed keywords

CREATININE; VIGABATRIN;

ADULT; AGING; ARTICLE; CASE REPORT; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG TOXICITY; EPILEPSY; HEMODIALYSIS; HUMAN; KIDNEY; KIDNEY FAILURE; KIDNEY FUNCTION; MALE; NEAR DROWNING; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RISK;

EID: 0029969838     PISSN: 10591311     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1059-1311(96)80043-4     Document Type: Article

References (13)

1. Grant, S.M. and Heel, R.C. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926.
2. Lippert, B., Metcalf, B.W., Jung, M.J. and Casara, P. 4-Aminohex-5-enoic acid, a selective catalytic inhibitor of 4-aminobutyric acid aminotransferase in mammalian brain. European Journal of Biochemistry 1977; 74: 441-445.
3. Jung, M.J., Lippert, B., Metcalf, B.W., Böhlen, P. and Schechter, P.J. γ-Vinyl-GABA, a new selective inhibitor of GABA-T. Effects on brain GABA metabolism in mice. Journal of Neurochemistry 1977; 29: 797-802.
4. Grove, J., Tell, G., Schechter, P.J., Koch-Weser, J., Warter, J.M., Marescaux, C. and Rumbach, L. Increased CSF γ-aminobutyric acid after treatment with γ-vinyl-GABA. Lancet 1980; ii: 647.
5. Gram, L., Blatt-Lyon, B. and Dam, M. γ-Vinyl-GABA: a single-blind trial in patients with epilepsy. Acta Neurologica Scandinavica 1983; 68: 34-39.
6. Browne, T.R., Mattson, R.H., Napoliello, M.J. et al. Multicenter single-blind study of γ-vinyl-GABA for refractory complex partial seizures. Epilepsia 1983; 24: 521.
7. Rey, E., Pons, G. and Olive, G. Vigabatrin. Clinical Pharmacokinetics 1992; 23: 267-278.
8. Saletu, B., Grünberger, J., Linzmayer, L., Schwartz, J.J., Haegele, K.D. and Schechter, P.J. Psychophysiological and psychometric studies after manipulating the Gaba system by vigabatrin, a GABA-transaminase inhibitor. International Journal of Psychophysiology 1986; 4: 63-80.
9. Browne, T.R., Mattson, R.H., Penry, J.K. et al. A multicentre study of vigabatrin for drug-resistant epilepsy. British Journal of Clinical Pharmacology 1989; 27 (Suppl. 1): 95S-100S.
10. Haegele, K.D. and Schechter, P.J. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clinical Pharmacology and Therapeutics 1986; 40: 581-586.
11. Friaux, A., Fröscher, W. and Brech, W. Vigabatrinelimination bei dialysepflichtiger Niereninsuffizienz. In: Epilepsie '93. (Stefan, H., Canger, R., Spiel, G., eds) Internationale Liga gegen Epilepsie, Berlin, 1994: pp. 457-459.
12. Tsanaclis, L.M., Wicks, J., Williams, J. and Richens, A. Determination of vigabatrin in plasma by reversed-phase high-performance liquid chromatography. Therapeutic Drug Monitoring 1991; 13: 251-253.
13. Haegele, K.D., Huebert, N.D., Ebel, M., Tell, G.P. and Schechter, P.J. Pharmacokinetics of vigabatrin: implications of creatinine clearance. Clinical Pharmacology and Therapeutics 1988; 44: 558-565.